In 2015, Obama pledged that by 2020, 1 million American students would be learning Mandarin. Students at Walnut Hills Elementary School in Greenville, Michigan, where parents earlier this year successfully rallied to save a Mandarin immersion programme from a phase-out. Photo: Facebook/ Walnut Hills Chinese Immersion Eight years later, to say the dynamics have shifted would be an understatement. Sino-US tensions now cast doubt over business opportunities in the mainland, while record-high proportions of Americans view China negatively. American students – whose numbers in China have declined from over 11,000…
Year: 2023
High Rice Prices Worldwide Likely to Continue Into 2024
WASHINGTON — Arnong Mungoei has farmed rice in Thailand’s Khon Kaen province for half a century. Working land some 500 kilometers northeast of Bangkok never made her rich, but it provided a dependable livelihood. But since February 2022 when Russia invaded Ukraine, global geopolitical tensions and weather conditions elsewhere have upended the rice markets and by 2023, worldwide rice prices had exploded. Yet Arnong said she made less than she has in years. “The mills [that buy rice] don’t increase the price. What can I do? I bring rice there…
China’s Official Character of the Year, ‘Zhen,’ Called ‘Fake’ by Netizens
WASHINGTON — China last week announced that “zhen” — a term officially defined as “self-inspire” — is the Chinese character of the year. The reaction online has been less than enthusiastic. China conducts an annual survey to choose characters and words that reflect the public’s prevailing sentiment or buzzworthy developments regarding the outgoing year. The government officially approves the final list, but not everyone on China’s highly censored internet celebrated the picks. “Fake and empty,” said one message on the Chinese social media platform Weibo. A Weibo blogger announced that…
O come all ye faithful – or else!
Between Dec. 17 and 27, while many countries are immersed in holiday cheer, North Koreans are being required to study intently, brave freezing temperatures to visit cultural sites, then have their loyalty scored in exams – all to mark the life of former leader Kim Jong Il, the father of current leader Kim Jong Un, residents in the country told Radio Free Asia. And if they don’t pass the test, they could face public criticism. Kim Jong Il died on Dec. 17, 2011, and every year since, the following 10…
US extends tariff exclusions on some Chinese goods till May
The office of US Trade Representative Katherine Tai on Tuesday announced a further extension of China “Section 301” tariff exclusions on 352 Chinese import and 77 Covid-19-related categories till May 31, 2024. The administration of former US president Donald Trump used Section 301 of the Trade Act of 1974, a statute aimed at combating trade partners’ unfair practices, to launch the China tariffs in 2018 and 2019. The import tariff exclusions include industrial components such as pumps and electric motors, some car parts and chemicals, bicycles and vacuum cleaners. The…
Israel warns of regional conflict risk as Iran tensions increase
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Israel’s defence minister has warned of a growing risk of a regional conflict in the Middle East as tensions with Iran increased. Yoav Gallant on Tuesday told a parliamentary committee that Israel was being attacked in a “multi-arena war” from seven areas, which he identified as Gaza, the West Bank, Lebanon, Syria, Iraq, Yemen and Iran. “We have already responded and acted in six of these arenas and I say…
AstraZeneca buys Chinese cancer therapy firm Gracell for $1.2bn
AstraZeneca has struck a deal to buy a Chinese cancer therapy company for up to $1.2bn (£950m), as Britain’s biggest drugmaker expands its footprint in its second-largest market. The Anglo-Swedish pharmaceutical firm announced on Tuesday it would acquire Gracell Biotechnologies, which is focused on a type of cancer therapy known as CAR-T that modifies a patient’s cells to fight the disease. The deal marks a further investment in cancer research and treatment, which accounts for about one-third of AstraZeneca’s business, as well as its continued push to expand in China.…
Taiwan elections: TikTok teams up with fact checkers to stop disinformation on site
“[The move] is part of our ongoing efforts to protect election integrity and support our community with authoritative information,” TikTok said on its website. 05:27 Taiwan election exposes generational rift over potential reunification with mainland China Taiwan election exposes generational rift over potential reunification with mainland China TikTok users would be directed to the guide once they searched for election-related information, viewed relevant videos, and watched live-streaming content, it said. The company said the guide contained links to Taiwan’s Central Election Commission (CEC) online resources about the election while MyGoPen…
Men still being favoured over women for Chinese government jobs, study warns
A data analysis by the Inspection Squad for Workplace Gender Discrimination looked at the annual recruitment drive for the national civil service and found more government positions were reserved for men than for women. The report, first published earlier this month, looked into the job requirements for all government positions advertised in October, a month before the annual civil service exam all candidates must pass if they want a permanent government job. The team found that of the nearly 40,000 jobs being advertised many specified that they were “men-only” or…
AstraZeneca set to make one of its first acquisitions in China
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is set to make one of its first acquisitions in China, announcing plans to acquire Gracell Biotechnologies for up to $1.2bn to increase its investment in cell therapies for treating cancer. The Anglo-Swedish drugmaker has been trying to use its status as one of the largest drugmakers in China by sales to hunt for potential deals. But, like rival large pharmaceutical companies, it has mainly signed licensing agreements for…